MariMed Inc. CEO Jon Levine praises President Trump for reclassifying cannabis as a Schedule III drug, marking a significant reform in US history. This move acknowledges cannabis’ medical uses and low abuse potential, opening doors for medical research and increased consumer acceptance. State-legal cannabis businesses, like MariMed, will no longer face IRS Section 280E tax penalties, resulting in improved profitability. MariMed is a leading multi-state cannabis operator known for its award-winning portfolio of brands, providing quality and innovation to consumers nationwide. For more information, visit www.marimedinc.com. Contact Zach Galasso at DPA Communications for media inquiries and Howard Schacter at MariMed for company inquiries.

Read more at GlobeNewswire: MariMed Statement on Historic Rescheduling of Cannabis